Clinical Trial Update: CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing CAPTEM (capecitabine + temozolomide) versus FOLFIRI as second-line therapy for neuroendocrine carcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• FLUOROURACIL (Fluorouracil)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Conditions: Neuroendocrine Carcinoma | Phase 2 | Status: TERMINATED